Adage Capital Partners
MRNA icon

Adage Capital Partners’s Moderna MRNA Stock Holding History

Adage Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-102,898
Closed -$6.88M – 930
2024
Q3 		$6.88M Sell
102,898
-149,555
-59% -$13.7M 0.01% 678
2024
Q2 		$30M Buy
+252,453
New +$31.9M 0.06% 334
2024
Q1 		– Sell
-249,453
Closed -$24.8M – 928
2023
Q4 		$24.8M Sell
249,453
-63,763
-20% -$5.36M 0.05% 362
2023
Q3 		$32.4M Buy
313,216
+55,191
+21% +$6.16M 0.07% 275
2023
Q2 		$31.4M Sell
258,025
-33,973
-12% -$4.53M 0.07% 291
2023
Q1 		$44.8M Sell
291,998
-44,018
-13% -$7.26M 0.1% 236
2022
Q4 		$60.4M Buy
336,016
+3,300
+1% +$540K 0.14% 171
2022
Q3 		$39.3M Buy
332,716
+205,258
+161% +$31.1M 0.1% 223
2022
Q2 		$18.2M Sell
127,458
-230,858
-64% -$33M 0.04% 454
2022
Q1 		$61.7M Sell
358,316
-17,600
-5% -$2.96M 0.12% 180
2021
Q4 		$95.5M Buy
375,916
+48,788
+15% +$14.3M 0.17% 127
2021
Q3 		$126M Buy
+327,128
New +$121M 0.25% 87
2020
Q3 		– Sell
-325,000
Closed -$20.9M – 795
2020
Q2 		$20.9M Buy
+325,000
New +$17.8M 0.05% 376

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Adage Capital Partners's MRNA Position: Q4 2024 in Review

Adage Capital Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 102,898 shares — an estimated $6.88M sold.

Adage Capital Partners first reported a position in MRNA in Q2 2020 and held it in 13 quarters. The position peaked at $126M in Q3 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Adage Capital Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Adage Capital Partners sold 102,898 Moderna shares in Q4 2024, an estimated $6.88M.
  • Adage Capital Partners first reported a position in Moderna in Q2 2020 and held it in 13 quarters.
  • Adage Capital Partners's Moderna position peaked at $126M in Q3 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.